TAXUS Liberté Paclitaxel-Eluting Stent Expanding in a Coronary A

Tags:: Stent FDA Taxus Liberté Paclitaxel-Eluting Coronary Medical Devices Multivu 34446

Please wait while the video loads.
You will need Adobe's Flash Player plugin to view this page properly.

Edit Video Details Editing Options

Submitter:
MultiVu
Visits: 71,292
Subscribers: 60
Comments: 0
Updated: 10-Jul-09
Videos: 1652

International
Comments: 0
Views: 642
Added: 10-Oct-08

Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the TAXUS Liberté stent early next month in the United States, following completion of the introduction of its TAXUS® Expresss2™ Atom™ Paclitaxel-Eluting Coronary Stent System, which was approved by the FDA last month. The TAXUS Liberté stent was launched in Europe and other international markets in 2005.

To view Multimedia News Release go to, http://www.prnewswire.com/mnr/bsci/34446/